News und Analysen
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global
![Sangamo Therapeutics Appoints John Markels to Its Board of Directors](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general
![Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on
![Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
![NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the Company will release fourth quarter and fiscal year 2019
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 5, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation
Agilent Technologies Inc. (NYSE: A) today announced it has reached an agreement with Twist Bioscience under which Twist has agreed to pay Agilent a sum of $22.5 million to settle Agilent’s claims
![Xencor to Present at Upcoming Investor Conferences](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
![Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
![Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
![Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
![Problem Zivilisationskrankheiten? Eher nicht für Aktionäre von Edwards Lifesciences...](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Problem Zivilisationskrankheiten? Eher nicht für Aktionäre von Edwards Lifesciences...
![Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020, following release of its fourth
![Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an
![Aduro Biotech: +142% – Alltag im No Brainer Club](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Aduro Biotech: +142% – Alltag im No Brainer Club
Für die Oktober-Empfehlung des No Brainer Clubs geht es weiter in die Höhe: Aduro Biotech (WKN: A14Q7F) bescherte NBC-Mitgliedern bis heute bereits einen Gewinn von +142%.
Nach dem Erreichen der
![Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has entered into a definitive agreement to acquire substantially all the assets and certain
![Premier Inc. Reports Fiscal 2020 Second-Quarter Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Premier Inc. Reports Fiscal 2020 Second-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 second quarter ended Dec. 31, 2019.
All results presented in this press release reflect continuing operations
![Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
![Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for
![Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing
![Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing
![Agilent Teams with Indian Institute of Technology Delhi to Enhance Biotherapeutics](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Teams with Indian Institute of Technology Delhi to Enhance Biotherapeutics
Agilent Technologies Inc. (NYSE: A) today announced that it is joining forces with the Indian Institute of Technology Delhi (IIT Delhi) to promote biopharmaceutical research.
Agilent and IIT